Showing results 1 to 1 of 1
Title | Author(s) | Issue Date | |
---|---|---|---|
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong Journal:Cost Effectiveness and Resource Allocation | 2020 |